Adellgene® Friedreich’s Ataxia

Kit for the determination of the GAA triplet repeats number of the FXN gene by fluorescent fragment analysis.

Information about the product

Friedreich’s ataxia (FRDA) is the most common hereditary ataxia and it´s an autosomal recessive degenerative disease.

The most common DNA abnormality associated with Friedreich’s ataxia (FRDA) is the expansion of a GAA triplet repeat polymorphism localized in the first intron of the gene encoding frataxin (FXN). Pathogenic GAA expansion alleles are in the size range of 50 to >1300 repeats with three different intervals:

  • healthy (between 5-30 repeats),
  • Mild symptoms (30-49 repeats)
  • Severe symptoms (50-1300 repeats)

Intended Use

Adellgene® Friedreich’s Ataxia is a semi-automated in vitro diagnostic kit designed for use in clinical laboratories which quantitatively determines the number of repetitions of GAA (guanine-adenine-adenine) in the first intron of the gene encoding frataxin (FXN) located in chromosome 9 resulting in Frie­dreich’s ataxia disease. It aims to aid diagnosis associated with clinical findings in Friedreich’s ataxia that span from mild to severe symptoms.

The use of this kit is the determination of healthy alleles who have between 5 to 30 GAA repeats, patients with mild phenotype (30-49 repeats), and severe (50-1300).

The technology is based on the polymerase chain reaction (PCR) of genomic DNA extracted from peripheral blood followed by fluorescence analysis of the size of the PCR fragments obtained by genetic analyser and conversion of that size in the number of GAA repeats.

Patients who can benefit from this determination are those referred by a specialist. The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Workflow

workflow adellgene

Results

Adellgene Friedreich s Ataxia Reaction 1 healthy allele 15R
Adellgene Friedreich s Ataxia Reaction 2 mutated allele more than 200R
Adellgene Friedreich s Ataxia title
Adellgene® Friedreich’s Ataxia 5

Limitations

  • Mutations (point mutations, insertions, deletions) at amplification primer sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the genotyping.
  • Data and result interpretation should be revised by qualified personnel.

Area:

Molecular Genetics, Neurology, Targeted study of specific pathologies

Technology:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SOPHiA DDM GEN2

Analytical platform for clinical genomics that enables the detection, annotation, and interpretation of genomic variants using artificial intelligence to support patient diagnosis and treatment. Detailed Description SOPHiA DDM™ Platform is an advanced solution for precision medicine workflows, with a renewed interface, web access, and new functionalities to accelerate genomic data analysis. It offers end‑to‑end workflows…
SOPHIA Genetics

PGT-SR (Preimplantation Genetic Testing for Chromosomal Structural Rearrangements)

PGT‑SR (Preimplantation Genetic Testing for Structural Chromosomal Rearrangements) is a solution aimed at the analysis of structural chromosomal rearrangements in embryos. According to the product literature, it is based on single‑cell whole‑genome amplification and NGS sequencing to detect embryos from patients with chromosomal abnormalities and select euploid embryos for transfer, with the aim of reducing…
Yikon Genomics
Next Generation Sequencing (NGS)

MaReCs (Mapping allele with resolved carrier state test)

MaReCs® (Allelic Mapping with Resolved Carrier Status) is a PGT‑SR technology that first identifies aneuploid or euploid embryos and then analyses translocation breakpoints and SNP linkage to differentiate carrier from non‑carrier euploid embryos. Detailed Description Principle of operation MaReCs® combines ChromSwift® technology with NGS sequencing to perform a CNV analysis and subsequently an SNP linkage…
Yikon Genomics
Next Generation Sequencing (NGS)

KaryoSeq (Integrated solution for PGT-M, PGT-SR and PGT-A)

KaryoSeq™ is a next‑generation sequencing (NGS)‑based solution for preimplantation genetic testing that enables PGT‑M, PGT‑SR and PGT‑A within a single workflow. It is designed for the analysis of DNA extracted from 3 to 10 trophectoderm cells of human embryos at the blastocyst stage. Detailed Description Principle of operation KaryoSeq™ is based on the MARSALA principle…
Yikon Genomics
Next Generation Sequencing (NGS)